McKenzie Kathryn B
Known title: Chief Financial OfficerCIK: 0001720001
Associated companies
Transaction History
| NEO | ▲ Buy | Option Exercise | 2,100 | $19K | 1/11/2022 | View on chart |
| NEO | ▲ Buy | Grant | 30,572 | $0 | 12/30/2021 | View on chart |
| NEO | ▲ Buy | Option Exercise | 5,000 | $45K | 12/22/2021 | View on chart |
| NEO | ▼ Sell | Open Market | 1,846 | $65K | 12/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.